Custom-Made brain cancer vaccine shows promise in early trial

This early-phase trial tests a personalized vaccine (NeoVax) made from each patient's unique tumor mutations, combined with radiation and the immunotherapy drug pembrolizumab (Keytruda), in people with newly diagnosed glioblastoma. The main goals are to see if the vaccine can be made safely and to check for side effects. About 56 participants are enrolled across several groups, some also receiving standard chemotherapy. The study is not yet recruiting and is actively following patients.